



Supplemental Figure 1: Correlation analysis of lesion size between CT and Dixon (A) and VIBE (B). X-axis displays mean size of lung lesion as obtained by CT, and y-axis displays corresponding values by Dixon and VIBE sequence. High correlations as expressed by the Spearman correlation coefficient ( $R$ ) are found between lesion size in CT and VIBE ( $R = 0.97$ ) and between CT and Dixon ( $R = 0.55$ ).

The difference between the two size measurement is shown by the Bland–Altman (C for lesion size in Dixon and D for lesion size in VIBE) on which the difference between 2 SUV measurements is plotted against their average: For lesion size Dixon mean difference is -2.6 mm; the 95% CIs are +8.6 and -13.8 mm, for lesion size VIBE the mean difference is -0.9 mm; the 95% CIs are +6.4 and -8.2 mm.




Supplemental Figure 2: Correlation analysis of tracer uptake between PET/CT and subsequent PET/MR as assessed by  $SUV_{max}$  in lung lesions (A) and normal lung parenchyma (B). X-axis displays quantitative values as obtained by PET/CT, and y-axis displays corresponding values by PET/MR. High correlations as expressed by the Spearman correlation coefficient ( $R$ ) are found for  $SUV_{max}$  ( $R = 0.50$  for normal lung parenchyma,  $R = 0.91$  for lung lesions) between findings from both modalities.


The difference between the two  $SUV$  measurement is shown by the Bland–Altman (C for  $SUV_{max}$  in lung lesions and D for  $SUV_{max}$  in the normal lung parenchyma) on which the difference between 2  $SUV$  measurements is plotted against their average: For  $SUV_{max}$ -healthy lung the mean difference is  $-0.23$   $SUV$ ; the 95% CIs are  $+0.18$  and  $-0.64$   $SUV$ , for  $SUV_{max}$ -lung lesion mean difference is  $+2.0$   $SUV$ ; the 95% CIs for  $SUV_{max}$  are  $+9.6$  and  $-5.6$   $SUV$ .



Supplemental Figure 3: 78-year old patient with bronchial carcinoma and a lung metastasis which was [ $^{18}\text{F}$ ]FDG positive and was seen in CT and both VIBE and Dixon sequence. Figure A, D and G show morphological datasets (A axial CT, D axial VIBE, G axial Dixon sequence). Figure B, E and H show the corresponding PET datasets (B PET of PET/CT, E PET AC of PET/MR, H PET NAC of PET/MR). The corresponding fused PET/CT is shown in Figure C, the fused PET/MR in F (fusion of VIBE with PET) and I (fusion of Dixon with PET).



Supplemental Figure 4: 66-year old patient with thyroid cancer and a lung metastasis which was [ $^{18}\text{F}$ ]FDG positive and was seen in CT and VIBE but not in the Dixon sequence. Figure A, D, G and I show morphological datasets (A axial CT, D axial VIBE, G and I axial Dixon sequence). Figure B, E and H show the corresponding PET datasets (B PET of PET/CT, E PET AC of PET/MR, H PET NAC of PET/MR). The corresponding fused PET/CT is shown in Figure C, the fused PET/MR in F (fusion of VIBE with PET).



Supplemental Figure 5: 41-year old patient with thyroid cancer and a lung metastasis (4 mm diameter) which showed no suspicious [ $^{18}\text{F}$ ]FDG uptake and was seen in CT but not in the Dixon and VIBE sequence. Figure A, D, G and I show morphological datasets (A axial CT, D axial VIBE, G and I axial Dixon sequence). Figure B, E and H show the corresponding PET datasets (B PET of PET/CT, E PET AC of PET/MR, H PET NAC of PET/MR). The corresponding fused PET/CT is shown in Figure C, the fused PET/MR in F (fusion of VIBE with PET).